Adaptimmune - Articles and news items

Breakthrough Therapy designation for Adaptimmune’s NY-ESO-1-T cell therapy

Industry news / 10 February 2016 / Victoria White

The Breakthrough Therapy designation was based on the results of a Phase I/II trial in patients with unresectable, metastatic or recurrent synovial sarcoma…

Adaptimmune initiates Phase I/II T-cell therapy study in NSCLC

Industry news / 18 December 2015 / Victoria White

This will be the first study of Adaptimmune’s unpartnered affinity enhanced T-cell therapy targeting MAGE-A10, a highly immunogenic member of the MAGE-A family of cancer testis antigens…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+